Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Assunto principal
Intervalo de ano de publicação
1.
Rev Gastroenterol Peru ; 41(2): 86-93, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34724689

RESUMO

INTRODUCTION: COVID-19 affects the liver, causing alteration in liver biochemistry tests such as aspartate transferase (AST), alanine transferase (ALT), alkaline phosphatase (ALP), total bilirubin and albumin. OBJECTIVE: To determine the prevalence of alteration in liver functions tests and associated factors for severity among Peruvian COVID-19 patients. MATERIALS AND METHODS: A descriptive, retrospective and cross-sectional study was performed in 4 public hospitals in Peru. Patients admitted to hospitalization wards and intensive care units with a diagnosis COVID-19 were enrolled. The evaluation of AST, ALT, ALP, totalbilirubin and albumin was performed. Associations with demographic and medical data were assessed. RESULTS: 1,100 patients were enrolled, of which 81.7% had altered liver function tests. Only 2.8% of the patients had cirrhosis and 2.1% hepatitis B/C virus. AST and ALT were altered at admission in 64.7% and 63.7%, of the patients respectively. Factors associated with liver injury were: being female OR=0.53 (95% CI: 0.39-0.73; p<0.01), dyslipidemia OR=1.72 (95% CI: 1.10-2.70; p=0.01), previous medication OR=1.56 (95% CI: 1.12 -2.16, p<0.01) and fever OR=1.43 (95% CI: 1.03-1.199, p=0.03). Disease severity was associated with levels of AST and ALT (p<0.01). Patients taking self-medication OR=1.56 (95% CI: 1.12-2.16; p<0.01) and paracetamol OR= 1.41 (95% CI:1.01-1.98; p=0.04) had higher risk of liver injury. Meanwhile, corticosteroids OR=0.55 (95% CI: 0.38-0.78; p<0.01) and enoxaparin OR=0.53 (95% CI: 0.35- 0.81; p<0.01) were protective factors. CONCLUSIONS: Peruvian patients with COVID-19 presented high prevalence of alteration in liver function tests, high levels of AST and ALT were related to disease severity.


Assuntos
COVID-19 , Estudos Transversais , Feminino , Humanos , Fígado , Testes de Função Hepática , Peru/epidemiologia , Estudos Retrospectivos , SARS-CoV-2
2.
Rev. gastroenterol. Perú ; 41(2)abr. 2021.
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1508582

RESUMO

Introduction: COVID-19 affects the liver, causing alteration in liver biochemistry tests such as aspartate transferase (AST), alanine transferase (ALT), alkaline phosphatase (ALP), total bilirubin and albumin. Objective: To determine the prevalence of alteration in liver functions tests and associated factors for severity among Peruvian COVID-19 patients. Materials and methods: A descriptive, retrospective and cross-sectional study was performed in 4 public hospitals in Peru. Patients admitted to hospitalization wards and intensive care units with a diagnosis COVID-19 were enrolled. The evaluation of AST, ALT, ALP, total bilirubin and albumin was performed. Associations with demographic and medical data were assessed. Results: 1,100 patients were enrolled, of which 81.7% had altered liver function tests. Only 2.8% of the patients had cirrhosis and 2.1% hepatitis B/C virus. AST and ALT were altered at admission in 64.7% and 63.7%, of the patients respectively. Factors associated with liver injury were: being female OR=0.53 (95% CI: 0.39-0.73; p<0.01), dyslipidemia OR=1.72 (95% CI: 1.10-2.70; p=0.01), previous medication OR=1.56 (95% CI: 1.12 -2.16, p<0.01) and fever OR=1.43 (95% CI: 1.03-1.199, p=0.03). Disease severity was associated with levels of AST and ALT (p<0.01). Patients taking self-medication OR=1.56 (95% CI: 1.12-2.16; p<0.01) and paracetamol OR= 1.41 (95% CI:1.01-1.98; p=0.04) had higher risk of liver injury. Meanwhile, corticosteroids OR=0.55 (95% CI: 0.38-0.78; p<0.01) and enoxaparin OR=0.53 (95% CI: 0.35- 0.81; p<0.01) were protective factors. Conclusions: Peruvian patients with COVID-19 presented high prevalence of alteration in liver function tests, high levels of AST and ALT were related to disease severity.


Introducción: La COVID-19 afecta al hígado, provocando alteración en las pruebas de función hepática como aspartato aminotransferasa (AST), alanina aminotransferasa (ALT), fosfatasa alcalina (FA), bilirrubina total y albúmina. Objetivo: Determinar la prevalencia de alteración en las pruebas de función hepática y su asociación con la severidad en pacientes peruanos con COVID-19. Materiales y métodos: Se realizó un estudio descriptivo, retrospectivo y transversal en 4 hospitales públicos del Perú. Se incluyeron pacientes admitidos en hospitalización y unidades de cuidados intensivos con diagnóstico de COVID-19. Se realizó la evaluación de AST, ALT, FA, bilirrubina total y albúmina. Se evaluaron las asociaciones con datos demográficos y médicos. Resultados: Se incluyeron 1,100 pacientes, de los cuales el 81,7% presentaba alteraciones en las pruebas de función hepática. Solo el 2,8% de los pacientes tenía cirrosis y el 2,1% infección por virus de la hepatitis B / C. Se encontraron niveles alterados de AST y ALT al ingreso en el 64,7% y 63,7% de los pacientes, respectivamente. Los factores asociados con alteración en pruebas de función hepáticas fueron: ser mujer OR = 0,53 (IC 95%: 0,39-0,73; p <0,01), dislipidemia OR=1,72 (IC 95%: 1,10-2,70; p=0,01), uso de medicación previa OR = 1,56 (IC del 95%: 1,12 -2,16, p <0,01) y fiebre OR = 1,43 (IC del 95%: 1,03-1,199, p = 0,03). La gravedad de la enfermedad se asoció con los niveles de AST y ALT (p <0,01). Los pacientes que se automedicaban OR = 1,56 (IC 95%: 1,12-2,16; p <0,01) y tomaban paracetamol OR = 1,41 (IC 95%: 1,01-1,98; p =0,04) tenían mayor riesgo de injuria hepática. Mientras tanto, los corticosteroides OR=0,55 (IC del 95%: 0,38-0,78; p <0,01) y la enoxaparina OR=0,53 (IC del 95%: 0,35-0,81; p <0,01) fueron factores protectores. Conclusiones: los pacientes peruanos con COVID-19 presentaron alta prevalencia de alteración en las pruebas de función hepática, niveles elevados de AST y ALT se relacionaron con la gravedad de la enfermedad.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA